✦ LIBER ✦

Hypersensitivity reactions to Patent Blue V in breast cancer surgery: a prospective multicentre study

✍ Scribed by BRENET, O.; LALOURCEY, L.; QUEINNEC, M.; DUPOIRON, D.; JAYR, C.; ROSAY, H.; MAVOUNGOU, P.; MONNIN, D.; ANCEL, B.; MAGET, B.; LOUVIER, N.; MALINOVSKY, J.-M.

Book ID: 119825810
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 143 KB
Volume: 57
Category: Article
ISSN: 0001-5172
DOI: 10.1111/aas.12003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

606 Feasibility of Sentinel Lymph Node D

606 Feasibility of Sentinel Lymph Node Detection with Radioisotopic Method Alone After a Grade IV Anaphylactic Reaction to Patent Blue in Breast Cancer Surgery

✍ L. Gaujal; I. Malka; J.g. Féron; C. Ngo; V. Fourchotte; F. Hugonnet; F. Laki; M. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 77 KB

Conservative surgery with and without ra

Conservative surgery with and without radiotherapy in elderly patients with early-stage breast cancer: A prospective randomised multicentre trial

✍ C. Tinterri; W. Gatzemeier; V. Zanini; L. Regolo; C. Pedrazzoli; E. Rondini; C. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 207 KB

To dilute or not to dilute? A study of t

To dilute or not to dilute? A study of the effect of dilution of patent blue dye on the identification rate of sentinel lymph nodes in breast cancer

✍ Katie Eyre; T. Oakley; J. Gill; R. Cutress; R. Nicol; A. Agrawal; C. Yiangou; M. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 39 KB

Adherence to the mediterranean diet and

Adherence to the mediterranean diet and risk of breast cancer in the European prospective investigation into cancer and nutrition cohort study

✍ Buckland, G.; Travier, N.; Cottet, V.; González, C.A.; Luján-Barroso, L.; Agudo, 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 French ⚖ 270 KB

P294 What is the key issue to evaluate a

P294 What is the key issue to evaluate adherence to endocrine treatment in breast cancer patients? Methodological results of a prospective study: Patient-reported outcomes in breast cancer patients undergoing endocrine therapy (PRO-BETh)

✍ R. Achleitner; A. Oberguggenberger; V. Meraner; C. Marth; B. Beer; J. Giesinger; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Is ERBB-2 A predictive marker for respon

Is ERBB-2 A predictive marker for response to primary chemotherapy for operable breast cancer: a prospective study in a phase ii randomized trial of doxorubicin/cyclophosphamide (AC) and doxorubicin/paclitaxel (AT)

✍ P. De Crémoux; V. Diéras; V. Le Doussal; A. Vincent-Salomon; M. Tubiana-Hulin; J 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 120 KB